NADIR ALI 4’ | Study 28k people: PCSK9 inhibitor… No mortality benefit
presents episode 1124 | Dr Nadir Ali
Low Carb Denver podcast
Animal studies: using PCSK9 inhibitor-like approach
results: higher risk of diabetes & visceral obesity &
higher fat in heart
WHY? It removes LDL receptor in liver & pancreas, that was
sucking up LDL from bloodstream…
LDL particle is not just cholesterol filled,
but is fat filled, so: more receptors &
fat is removed from circulation, giving
fatty liver & fatty pancreas
People born with PCSK9 DEFICIENCY: they have higher risk:
-diabetes; higher weight; more visceral obesity
Fourier PCSK9 trials, 28k patients: half control; half: Repatha
results: Repatha group dropped LDL: to 30mg/dL [.8 mmol/L] Control: 90mg/dL
OUTCOME: no mortality difference!
“Abject failure of the drug”
SUM: PCSK9 inhibitor: higher risk
-diabetes, visceral obesity
Human genetic trials: same result
“Do not tell patients this drug beneficial”
Original Youtube: https://youtu.be/6YLrW-390wI?si=j7Fg7lTKxJ3Fsn5n
This site will never use corruptible, epidemiological survey research as causal science.
For each short/sharable video, the original Youtube links are provided
None of this content is intended to be individual, personalized medical advice.
We hope you find value for yourself in these short videos &
find them easy to share with loved ones!
The DoctorsToTrust videos are for general informational purposes only
and do not constitute the practice of medicine, nursing or other
professional health care services, including the giving of medical advice,
and no doctor/patient relationship is formed. The use of information on this podcast
or materials linked from this podcast is at the user’s own risk.
The content of this podcast is not intended to be a substitute for
professional medical advice, diagnosis, or treatment. Users should not disregard or
delay in obtaining medical advice for any medical condition they may have and
should seek the assistance of their health care professionals for any such conditions.